Trial Profile
An Expanded Access Program for Elotuzumab in Combination With Lenalidomide Plus Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 04 Dec 2023
Price :
$35
*
At a glance
- Drugs Dexamethasone (Primary) ; Elotuzumab (Primary) ; Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Expanded access; Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 05 Oct 2016 Status changed from recruiting to completed.
- 26 Feb 2015 New trial record